Corcos J, Fournier C
Department of Urology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
Urology. 1999 Nov;54(5):815-8. doi: 10.1016/s0090-4295(99)00269-1.
To assess the long-term (4-year) follow-up of urethral submucosal collagen injection for the treatment of stress urinary incontinence (SUI). Submucosal collagen injections are an acceptable alternative to surgery in the treatment of selected cases of SUI. Most published studies report 1 to 2-year results, with long-term data still being questioned despite the low morbidity and cost-effectiveness of this relatively recent technique.
Forty women with genuine SUI confirmed by clinical and urodynamic evaluation were treated with periurethral collagen injection. Clinical and urodynamic follow-up lasted an average of 50 months (range 47 to 55).
Totally favorable results, including improvement (40%) and cure (30%), were recorded in 28 patients. Other than three lower urinary tract infections, no complication was noted. For the entire group of patients, the average number of injections in the first 6 months was 2.2, with an average volume of 9.0 mL of collagen injected. The reinjection rate ("top up injection" after completion of treatment) was 33% in an average of 20 months, and the average amount of collagen used for this purpose was 5 mL.
The safety, low morbidity, and long-term outcome of periurethral collagen injection for genuine SUI are encouraging. Multivariable analysis involving a larger number of patients is necessary to determine the predictive factors of success or failure to better define the indications for this noninvasive procedure.
评估尿道黏膜下注射胶原蛋白治疗压力性尿失禁(SUI)的长期(4年)随访情况。黏膜下注射胶原蛋白是治疗某些SUI病例的一种可接受的手术替代方法。大多数已发表的研究报告的是1至2年的结果,尽管这种相对较新的技术发病率低且具有成本效益,但长期数据仍受到质疑。
对40名经临床和尿动力学评估确诊为真性SUI的女性进行尿道周围胶原蛋白注射治疗。临床和尿动力学随访平均持续50个月(范围47至55个月)。
28例患者取得了完全良好的结果,包括改善(40%)和治愈(30%)。除3例下尿路感染外,未观察到其他并发症。对于整个患者组,前6个月的平均注射次数为2.2次,平均注射胶原蛋白量为9.0 mL。再注射率(治疗完成后的“补充注射”)平均在20个月时为33%,为此目的使用的胶原蛋白平均量为5 mL。
尿道周围胶原蛋白注射治疗真性SUI的安全性、低发病率和长期结果令人鼓舞。需要对更多患者进行多变量分析,以确定成功或失败的预测因素,从而更好地界定这种非侵入性手术的适应症。